Acurx Pharma Highlights MRSA Antibiotic Data Preserving Gut Microbiome

Añadido: 2026-05-25

[00:00:00]From the New York Stock Exchange, I'm Jane King for News Out. Acurex Pharmaceuticals presented a scientific poster at the 35th ESMID global conference in Munich, evaluating the microbiome effects of its DNA inhibitors in a pre-clinical MRSA infection model.

[00:00:18]Acurex compounds reduced MRSA tissue burden while maintaining substantially higher gut microbial diversity compared to other markers associated with dispiosis. Microbiome preservation appears to be a class effect of DNA inhibitors, a novel finding not previously reported with any new antibiotic class. From the New York Stock Exchange, I'm Jane King for News Out.